Cargando…

RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?

BACKGROUND: Noonan syndrome (NS) is associated with germline Ras signaling pathway mutations, RAS overactivation and increased tumorigenesis risk. Rosette-forming glioneuronal tumors (RFGT) are rare indolent tumors. We report the molecular profiling of two patients with NS and RFGT. PATIENT 1: A 22-...

Descripción completa

Detalles Bibliográficos
Autores principales: Shatara, Margaret, Varga, Elizabeth A, Boué, Daniel R, Martin, Lisa, Rusin, Jerome A, Rodriguez, Diana P, Jones, Jeremy, McAllister, Aaron, Leonard, Jeffrey R, Pindrik, Jonathan, Schieffer, Kathleen M, Leraas, Kristen M, Lichtenberg, Tara M, Mardis, Elaine R, Cottrell, Catherine E, Osorio, Diana S, AbdelBaki, Mohamed S, Finlay, Jonathan L
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2020
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715866/
http://dx.doi.org/10.1093/neuonc/noaa222.747
_version_ 1783619055923494912
author Shatara, Margaret
Varga, Elizabeth A
Boué, Daniel R
Martin, Lisa
Rusin, Jerome A
Rodriguez, Diana P
Jones, Jeremy
McAllister, Aaron
Leonard, Jeffrey R
Pindrik, Jonathan
Schieffer, Kathleen M
Leraas, Kristen M
Lichtenberg, Tara M
Mardis, Elaine R
Cottrell, Catherine E
Osorio, Diana S
AbdelBaki, Mohamed S
Finlay, Jonathan L
author_facet Shatara, Margaret
Varga, Elizabeth A
Boué, Daniel R
Martin, Lisa
Rusin, Jerome A
Rodriguez, Diana P
Jones, Jeremy
McAllister, Aaron
Leonard, Jeffrey R
Pindrik, Jonathan
Schieffer, Kathleen M
Leraas, Kristen M
Lichtenberg, Tara M
Mardis, Elaine R
Cottrell, Catherine E
Osorio, Diana S
AbdelBaki, Mohamed S
Finlay, Jonathan L
author_sort Shatara, Margaret
collection PubMed
description BACKGROUND: Noonan syndrome (NS) is associated with germline Ras signaling pathway mutations, RAS overactivation and increased tumorigenesis risk. Rosette-forming glioneuronal tumors (RFGT) are rare indolent tumors. We report the molecular profiling of two patients with NS and RFGT. PATIENT 1: A 22-year-old male with NS was diagnosed with RFGT after partial tumor resection followed by focal irradiation. He was enrolled on a comprehensive genomic profiling study involving paired tumor-normal whole exome sequencing and RNA sequencing of the disease-involved tissue, revealing a germline PTPN11 alteration (p.Gly60Ala) consistent with NS, and a somatic deletion (p.Ile442_Thr454del) in PIK3R1 and a somatic variant (p.Lys656Glu) in FGFR1 with concomitant increased expression of PIK3R1 and FGFR1 by RNA-sequencing. The patient remains without tumor progression now nine months since irradiation. PATIENT 2: A 19-year-old male with persistent headaches, underwent a brain MRI demonstrated multiple abnormal signals in the pineal region and midbrain. He had a stereotactic biopsy revealing RFGT. He was enrolled on the genomic study revealing a germline PTPN11 alteration (p.Asn308Asp) resulting in a new diagnosis of NS. Several family members were subsequently identified with clinical features of NS, including his mother and two siblings, enabling appropriate counseling. Two somatic variants were found in trans in PIK3R1 (p.Thr454_Phe456del and p.Glu451_Asn453delinsAsp), and a somatic variant (p.Val695Met) in FGFR1, with resultant overexpression of PIK3R1. The patient is monitored with surveillance imaging. CONCLUSION: We report the molecular profiling of two patients with NS and RFGT; strongly suggesting their connection to RASopathies through the overactivation of the MAPK and PI3K/AKT/mTOR signaling pathways.
format Online
Article
Text
id pubmed-7715866
institution National Center for Biotechnology Information
language English
publishDate 2020
publisher Oxford University Press
record_format MEDLINE/PubMed
spelling pubmed-77158662020-12-09 RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION? Shatara, Margaret Varga, Elizabeth A Boué, Daniel R Martin, Lisa Rusin, Jerome A Rodriguez, Diana P Jones, Jeremy McAllister, Aaron Leonard, Jeffrey R Pindrik, Jonathan Schieffer, Kathleen M Leraas, Kristen M Lichtenberg, Tara M Mardis, Elaine R Cottrell, Catherine E Osorio, Diana S AbdelBaki, Mohamed S Finlay, Jonathan L Neuro Oncol Craniopharyngioma and Rare Tumors BACKGROUND: Noonan syndrome (NS) is associated with germline Ras signaling pathway mutations, RAS overactivation and increased tumorigenesis risk. Rosette-forming glioneuronal tumors (RFGT) are rare indolent tumors. We report the molecular profiling of two patients with NS and RFGT. PATIENT 1: A 22-year-old male with NS was diagnosed with RFGT after partial tumor resection followed by focal irradiation. He was enrolled on a comprehensive genomic profiling study involving paired tumor-normal whole exome sequencing and RNA sequencing of the disease-involved tissue, revealing a germline PTPN11 alteration (p.Gly60Ala) consistent with NS, and a somatic deletion (p.Ile442_Thr454del) in PIK3R1 and a somatic variant (p.Lys656Glu) in FGFR1 with concomitant increased expression of PIK3R1 and FGFR1 by RNA-sequencing. The patient remains without tumor progression now nine months since irradiation. PATIENT 2: A 19-year-old male with persistent headaches, underwent a brain MRI demonstrated multiple abnormal signals in the pineal region and midbrain. He had a stereotactic biopsy revealing RFGT. He was enrolled on the genomic study revealing a germline PTPN11 alteration (p.Asn308Asp) resulting in a new diagnosis of NS. Several family members were subsequently identified with clinical features of NS, including his mother and two siblings, enabling appropriate counseling. Two somatic variants were found in trans in PIK3R1 (p.Thr454_Phe456del and p.Glu451_Asn453delinsAsp), and a somatic variant (p.Val695Met) in FGFR1, with resultant overexpression of PIK3R1. The patient is monitored with surveillance imaging. CONCLUSION: We report the molecular profiling of two patients with NS and RFGT; strongly suggesting their connection to RASopathies through the overactivation of the MAPK and PI3K/AKT/mTOR signaling pathways. Oxford University Press 2020-12-04 /pmc/articles/PMC7715866/ http://dx.doi.org/10.1093/neuonc/noaa222.747 Text en © The Author(s) 2020. Published by Oxford University Press on behalf of the Society for Neuro-Oncology. http://creativecommons.org/licenses/by-nc/4.0/ This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/), which permits non-commercial re-use, distribution, and reproduction in any medium, provided the original work is properly cited. For commercial re-use, please contact journals.permissions@oup.com
spellingShingle Craniopharyngioma and Rare Tumors
Shatara, Margaret
Varga, Elizabeth A
Boué, Daniel R
Martin, Lisa
Rusin, Jerome A
Rodriguez, Diana P
Jones, Jeremy
McAllister, Aaron
Leonard, Jeffrey R
Pindrik, Jonathan
Schieffer, Kathleen M
Leraas, Kristen M
Lichtenberg, Tara M
Mardis, Elaine R
Cottrell, Catherine E
Osorio, Diana S
AbdelBaki, Mohamed S
Finlay, Jonathan L
RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title_full RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title_fullStr RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title_full_unstemmed RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title_short RARE-37. NOONAN SYNDROME AND GLIONEURONAL TUMORS: A CENTRAL NERVOUS SYSTEM CANCER PREDISPOSITION ASSOCIATION?
title_sort rare-37. noonan syndrome and glioneuronal tumors: a central nervous system cancer predisposition association?
topic Craniopharyngioma and Rare Tumors
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7715866/
http://dx.doi.org/10.1093/neuonc/noaa222.747
work_keys_str_mv AT shataramargaret rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT vargaelizabetha rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT bouedanielr rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT martinlisa rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT rusinjeromea rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT rodriguezdianap rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT jonesjeremy rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT mcallisteraaron rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT leonardjeffreyr rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT pindrikjonathan rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT schiefferkathleenm rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT leraaskristenm rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT lichtenbergtaram rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT mardiselainer rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT cottrellcatherinee rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT osoriodianas rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT abdelbakimohameds rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation
AT finlayjonathanl rare37noonansyndromeandglioneuronaltumorsacentralnervoussystemcancerpredispositionassociation